CytoMed Therapeutics (GDTC) Stock Price, News & Analysis

Company Overview

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore. The company was incorporated in 2018 and is headquartered in Singapore.

Key Stats

• Today's Range: $0.95 to $1.05
• 50-Day Range: $0.76 to $1.32
• 52-Week Range: $0.68 to $3.68
• Volume: 5,287 shs
• Average Volume: 20,460 shs
• Market Capitalization: $12.13 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

CytoMed Therapeutics Stock Analysis - MarketRank™

CytoMed Therapeutics scored higher than 28% of companies evaluated by MarketBeat, and ranked 735th out of 852 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

CytoMed Therapeutics has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

CytoMed Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

CytoMed Therapeutics has a P/B Ratio of 2.28. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.39% of the float of CytoMed Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

CytoMed Therapeutics has a short interest ratio ("days to cover") of 1.99, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in CytoMed Therapeutics has recently decreased by 32.30%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

CytoMed Therapeutics does not currently pay a dividend.

Dividend Growth

CytoMed Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: N/A

News Sentiment

CytoMed Therapeutics has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.84 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for CytoMed Therapeutics this week, compared to 1 article on an average week.

Company Ownership

• Score: 2.9 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $128,800.00 in company stock, which represents 1.0622% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, CytoMed Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $128,800.00 in company stock and sold $0.00 in company stock.

Percentage Held by Institutions

0.04% of the stock of CytoMed Therapeutics is held by institutions.

Company Calendar

• Today: 7/01/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:GDTC
• CIK: 1873093
• Web: w2.cytomed.sg
• Phone: 65-6250-7738
• Fax: N/A
• Employees: N/A
• Year Founded: 2018

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.06
• Current Ratio: 5.17
• Quick Ratio: 5.17

Sales & Book Value

• Annual Sales: $250 thousand
• Price / Sales: 48.50
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.45 per share
• Price / Book: 2.28

Miscellaneous

• Outstanding Shares: 11,830,000
• Free Float: N/A
• Market Cap: $12.13 million
• Optionable: Not Optionable
• Beta: 0.01